Lawyers for the Lifecycle of Food, Dietary Supplement & Cosmetic Products; Brand to Generic Drug Leaders

ATU Arguments Prevail Again in One of the “Biggest Patent Cases of 2018”

Law360 recently named the Federal Circuit’s July ruling in St. Regis Mohawk Tribe, et al. v. Mylan Pharmaceuticals Inc., et al., an appeal from the United States Patent Trial and Appeal Board, as one of MORE >

see all news >

Food & Beverage

We support clients throughout the entire lifecycle of products aimed at improving the population's health and wellness: food and beverages, nutritional supplements, cosmetics, medical devices and pharmaceuticals.


Intellectual Property

Drawing heavily on our IP, patent and trademark expertise, we provide our clients with business advice and strategies that enhance product value and head off future litigation.



We are deeply experienced in FDA and FTC disputes, patent and trademark infringement cases, class actions, breach of contract and unfair competition claims. We are renowned in the area of Paragraph IV litigation, where companies challenge brand name patents so that medications can be marketed in generic forms.


Brand to Generic Drug

We provide counseling both to generic companies seeking to challenge patents and bring drugs to market, and to brand name pharmaceutical companies seeking to strategically patent and protect their brand name products in the long term.

What's New
  • news

    Amin Talati Upadhye, LLP Team Wins Again at the ITC in False Advertising Case

    On July 9, 2018, Partners Joseph Cwik and Erin Conway earned a complete victory at the U.S. International Trade Commission (“ITC”) for the firm’s client ECI Pharmaceuticals LLC (“ECI”) when Complainants Valeant Pharmaceuticals North America LLC and Valeant Pharmaceuticals International, Inc. withdrew all allegations in their Amended Complaint against ECI and moved to terminate their […]

  • news

    Three’s Company! Al-Mondihry, Bond and Wasserman In One Article On New FTC Leadership

    ATU DC’s Rend Al-Mondhiry, Katie Bond, and Ivan Wasserman have been featured in a recent article published by Natural Products Insider assessing the potential issues with dietary supplement advertising by the new FTC leadership under the Republican Administration. To read the full article, please click HERE.

  • news

    Shashank Upadhye will be Speaking at ACI’s 12th Annual Paragraph IV Disputes Conference

    Shashank Upadhye will be speaking at ACI’s 12th Annual Paragraph IV Disputes conference in New York on April 23, 2018. The Paragraph IV conference is one of the biggest and most important conferences in the brand-generic drug industry. Learn more and attend the conference HERE.